Apellis Pharmaceuticals, Inc. short interest in 2026
In 2026, Apellis Pharmaceuticals, Inc.'s disclosed short interest ran from 14.31% of shares outstanding on 15 Jan 2026 to 8.40% on 30 Apr 2026, a change of -5.91 percentage points. The year's high was 19.86% on 31 Mar 2026 and its low 8.40% on 30 Apr 2026, averaging 15.80% across 8 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.12 days on 27 Feb 2026. Full history: Apellis Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 14.31% (15 Jan 2026)
- End of year
- 8.40% (30 Apr 2026)
- Change
- -5.91 pp
- High
- 19.86% (31 Mar 2026)
- Low
- 8.40% (30 Apr 2026)
- Average
- 15.80%
- Highest days to cover
- 12.12 (27 Feb 2026)
- SEC filings marked
- 3
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 14.31% | 5.26 | results (8-K) |
| 30 Jan 2026 | 16.79% | 4.76 | |
| 13 Feb 2026 | 19.51% | 11.26 | |
| 27 Feb 2026 | 18.13% | 12.12 | 10-K filed |
| 13 Mar 2026 | 18.12% | 11.91 | |
| 31 Mar 2026 | 19.86% | 2.64 | |
| 15 Apr 2026 | 11.25% | 1.75 | |
| 30 Apr 2026 | 8.40% | 3.06 |
See also: Apellis Pharmaceuticals, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.